Life sciences and healthcare Van Lanschot Kempen

Life Sciences & Healthcare

One-stop shop for European life sciences companies

Life sciences & healthcare

Established as the premier, pan-European, specialist investment bank in the life sciences & healthcare sector, Van Lanschot Kempen is a trusted adviser with many repeat clients. We are your one-stop shop with top-tier international expertise and a global investor network. Our Life Sciences & Healthcare team combines in-depth sector knowledge, scientific background and business experience. For corporate clients, our goal is to ensure that all M&A and ECM transaction processes run smoothly, while achieving the best results. For investors, we offer high-quality analysis of the broadest small/mid-cap European life sciences coverage, as well as trade execution and liquidity through our specialised marketing and trading services.

Unrivalled track record

Consistently successful results for our clients have led to high levels of repeat business, helping Van Lanschot Kempen build outstanding credentials over the years.

  • Leading pan-European bank for ECM transactions in the life sciences & healthcare sector

  • Outstanding stock-picking track record, consistently beating healthcare indices

  • Connecting EU life sciences companies with global institutional investors

  • Experts in block trades and providing liquidity

  • More than 175 successfully executed transactions, raising over €10 billion

  • Access to both European and US capital markets

Products and services

Benefit from our specialist sector knowledge with solutions tailored exclusively to life sciences & healthcare.

Mergers & acquisitions

For both listed and private companies, with extensive experience in sell-side and buy-side.

Corporate advisory

Buy- and sell-side advisory for cross-border deals, strategic financial advice on capital structuring, and ECM services such as IPOs and public-to-private transactions.

Transactions

Great cooperation makes for excellent transactions. Our outstanding sector knowledge combined with a strong focus on understanding stocks and companies ensures we have a superior industry network and distribution power, leading to a successful track record in the market. 

Pending
Pharming logo
Sole Financial Adviser
SEK 725 million
Recommended cash offer to acquire Abliva
Right Arrow in Circle
See all transactions

Coverage list

Curious to know more?

Jan de Kerpel Van Lanschot Kempen

Jan De Kerpel

Managing Director
Life Sciences and Healthcare

EmailMail Jan De Kerpel
Nadine Maalouf Van Lanschot Kempen

Nadine Maalouf

Managing Director
Life Sciences and Healthcare

Suzanne van Voorthuizen

Head of Life Sciences Equity Research